ABVC BioPharma, Inc. (ABVC) Stock
Healthcare · Biotechnology · Member of Other US Stocks
ABVC BioPharma, Inc. (ABVC) closed at USD 1.02 on 2026-10-14, a change of -64.9 % over the past year, with a market capitalization of USD 24.89M.
ABVC BioPharma, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 1.02 |
| 2026-10-13 | 0.98 |
| 2026-10-12 | 0.98 |
| 2026-10-09 | 1.00 |
| 2026-10-08 | 0.98 |
| 2026-10-07 | 1.00 |
| 2026-10-06 | 0.97 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
ABVC BioPharma, Inc. key figures
- Previous close
- USD 1.02 (2026-10-14)
- 1-year change
- -64.9 %
- Market cap
- USD 24.89M
- Enterprise value
- USD 28.95M
- P/E ratio (trailing)
- -3.22
- P/E ratio (forward)
- -2.12
- EPS (trailing)
- -0.29
- EPS (forward)
- -0.44
- PEG ratio
- n/a
- Price to book
- 2.31
- Revenue growth
- n/a
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 3.64
- Employees
- 16
- Analyst consensus (third-party)
- none
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About ABVC BioPharma, Inc.
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for ABVC BioPharma, Inc. and compare it with other stocks.
Analyze ABVCAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell ABVC BioPharma, Inc. shares.